Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.

A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. Will it continue?

Sarepta Therapeutics今日宣布与Arrowhead ...

周三，知名投资公司Needham调整了专注于罕见遗传疾病的生物制药公司Sarepta Therapeutics (NASDAQ:SRPT)的股票目标价。新的目标价设定为202美元，略低于此前的205美元。尽管目标价有所调整，Needham仍然维持了对该公司股票的买入评级。

On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...

Sarepta Therapeutics今天早些时候披露了与Arrowhead的新合作关系，收购了四个临床阶段的管线项目，涵盖神经肌肉、肺部和中枢神经系统（CNS）疾病等多个治疗领域。此外，该交易还包括三个临床前CNS项目和六个发现阶段项目。

Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...

根据合作协议，Arrowhead公司将获得5亿美元的预付款和3.25亿美元的股权投资。此外，在接下来的5年里，公司还将收到2.5亿美元的额外款项。Arrowhead公司还将获得3亿美元与近期临床试验入组相关的里程碑付款，以及高达103亿美元的额外里程 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.C2GW7kSb.js ...

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Gil Blum, an analyst from Needham, reiterated the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target was ...